ADARB1 and central nervous system cancer: To further identify the effect of the ADARB1-mediated AKT signaling axis in TMZ-resistant GBM cells, we treated TMZ-resistant glioma cells with the AKT inhibitor MK2206 (Mehnert et al., 2019).